Watson Can't Prove Rapamune Patent Invalid, Judge Says

Law360, Los Angeles (January 30, 2013, 9:51 PM ET) -- A Delaware federal judge on Wednesday rejected Watson Pharmaceuticals Inc.'s claims that Pfizer Inc.'s patent for the organ rejection drug Rapamune was invalid, handing Pfizer a victory in its efforts to halt abbreviated new drug applications for generic versions of the drug.

U.S. District Judge Richard G. Andrews ruled Watson had failed to prove its arguments that U.S. Patent Number 5,100,899, titled “Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof,” was invalid due to obviousness, written description and derivation....
To view the full article, register now.